--- title: "HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma" type: "News" locale: "en" url: "https://longbridge.com/en/news/287199734.md" description: "In the FRUSICA-2 registration study, there was a notable 63% decrease in the risk of disease progression or death. The study also reported a median progression-free survival (PFS) of 22.2 months. These findings indicate a significant improvement in outcomes for participants involved in the study." datetime: "2026-05-21T10:02:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287199734.md) - [en](https://longbridge.com/en/news/287199734.md) - [zh-HK](https://longbridge.com/zh-HK/news/287199734.md) --- # HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma In the FRUSICA-2 registration study, there was a notable 63% decrease in the risk of disease progression or death. The study also reported a median progression-free survival (PFS) of 22.2 months. These findings indicate a significant improvement in outcomes for participants involved in the study. ### Related Stocks - [HCM.US](https://longbridge.com/en/quote/HCM.US.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [517110.CN](https://longbridge.com/en/quote/517110.CN.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [00013.HK](https://longbridge.com/en/quote/00013.HK.md) ## Related News & Research - [Twin Capital Management Inc. Grows Stock Position in UnitedHealth Group Incorporated $UNH](https://longbridge.com/en/news/287213128.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)